Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

38 results about "Myc proteins" patented technology

Construction method and application of gastric adenocarcinoma transgenic mouse model

ActiveCN119174414ACompound screeningApoptosis detectionGenes mutationActivating mutation
The invention discloses a construction method and application of a gastric adenocarcinoma transgenic mouse model, and the construction method comprises the following steps: overexpressing or increasing the MYC gene expression quantity or MYC protein activity in gastric mucosa epithelial cells of a mouse by using transgenosis and hybridization technologies, and activating KRAS gene mutation in the gastric mucosa epithelial cells at the same time, thereby obtaining the gastric adenocarcinoma transgenic mouse model. The Kras protein is abnormal in function and is continuously in an activated state, and the finally obtained mouse is the gastric adenocarcinoma transgenic mouse model. According to the invention, the Myc gene overexpression and KRAS activation mutation double-gene mutation mouse spontaneous gastric cancer animal model is constructed, and the method is simpler. The gastric cancer tumor formation time of the mouse model is shortened, the tumor formation rate is up to 100%, and the tumor formation effect is stable. Only tumor formation is performed in the stomach through induction, and tumor formation has high specificity. The animal model is determined to be adenocarcinoma in gastric cancer through pathological section and immunohistochemical staining, has good clinical representativeness, and can be applied to later development or screening of gastric cancer drugs.
Owner:SHANDONG UNIV

c-Myc protein inhibitor, and preparation method therefor and use thereof

Provided are a c-Myc protein inhibitor, and a preparation method therefor and use thereof. The c-Myc protein inhibitor selectively inhibits c-Myc protein. Therefore, the inhibitor can be used for prevention and treatment of diseases related to c-Myc protein disorders, such as cancers, cardiovascular and cerebrovascular diseases, diseases related to virus infection.
Owner:SUZHOU KINTOR PHARMA

Stapled peptide compounds selectively degrading myc protein, methods of making and using the same

PendingCN122628219ALysosomeApoptosis
The application discloses a stapled peptide compound for selectively degrading MYC protein, a preparation method and application thereof; the compound is sequentially connected in the N-terminal to C-terminal direction by a peptide recognition segment, a flexible linker and a chaperone-mediated autophagy recognition motif KFERQ or a similar motif; the peptide recognition segment is introduced by an (i, i+7) site alkenyl amino acid and a Grubbs catalytic RCM reaction to form a full carbon hydrogen stapling bridge to stabilize the alpha-helix conformation; stapled modification of a typical compound MAX-7 significantly improves the alpha-helix content, the protease stability and the cell penetration, so that the compound can efficiently enter cells and be located in lysosomes, and MYC protein is selectively degraded through the CMA pathway; in-vitro experiments show that MAX-7 can inhibit the proliferation, migration and invasion of various MYC-driven tumor cells, and induce apoptosis; the application provides a brand-new lysosome-directed degradation strategy for the "undruggable" target MYC, and establishes a universal technical platform which can be popularized to other difficult drug proteins.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Inhibitors of MYC and uses thereof

Disclosed are substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs). The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC. The disclosed PROTACs are shown to induce degradation of c-MYC protein. The substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs) disclosed, herein may be utilized as therapeutics for treating cancer and cell proliferative disorders.
Owner:NORTHWESTERN UNIV

Application of targeted P5CS and c-Myc binding site in indirect screening of targeted c-Myc protein inhibitor and method of targeted P5CS and c-Myc binding site

The invention discloses a screening method of a small-molecule inhibitor targeting protein interacting with c-Myc protein and application of the small-molecule inhibitor. The screening method comprises the following steps: taking hotspot residues Ser79, Ser117, Arg159, Thr299, Ser301, Val303, Met305 and Lys311 of a P5CSGK structural domain as pockets; the invention relates to a polypeptide containing 15 amino acids of c-Myc, a binding interface of the c-Myc protein and P5CS is determined, the binding interface is used as a site for screening small-molecule inhibitors to carry out drug screening of indirect targeting c-Myc protein, nine small-molecule inhibitors are screened, and the screened inhibitors can be used as antitumor drugs.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

Protein degradation agent

The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation can degrade various proteins including c-Myc protein, and therefore can be used for prevention and treatment of diseases related to disorders of various proteins including c-Myc protein, such as cancer; cardiovascular and cerebrovascular diseases, and viral infection-related diseases.
Owner:SUZHOU KINTOR PHARMA

Immortalization of splenic and peripheral blood macrophages using a multi-cistronic v-raf / v-myc lentivirus

Vectors and methods are disclosed for immortalizing mammalian cells by co-expression of v-raf and v-myc proteins. A replication-defective viral vector is used for improved safety. The vector comprises an optional marker gene, and is especially useful for producing an immortalized macrophage by a method that involves contacting the vector with a monocyte, proliferatively growing the monocyte, growing the monocytic cell on a solid surface, and then growing the monocytic cell on a porous surface. An immortalized macrophage is also disclosed.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC

Use of YW2301 in the preparation of a medicine for resisting Burkitt lymphoma

The application discloses application of YW2301 in preparation of a medicine for resisting Burkitt lymphoma, utilizes CCK8 cell activity experiment to detect the inhibition ability of YW2301 on Raji and CA46 cell proliferation, constructs a NON / SCID subcutaneous transplantation tumor model by using a Raji cell line, evaluates the therapeutic significance of YW2301 on Burkitt lymphoma, YW2301 can effectively inhibit the tumorigenicity of Burkitt lymphoma cells and the growth speed of the transplantation tumor, and adopts immunohistochemical staining to detect the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma transplantation tumor tissue section, YW2301 can effectively down-regulate the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma tissue, and further proves that YW2301 can be used as a candidate small molecule for targeted treatment of Burkitt lymphoma.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

Application of circZFAND6 as target spot in preparation of product for treating ovarian cancer

The invention discloses application of circZFAND6 as a target spot in preparation of a product for treating ovarian cancer, and belongs to the technical field of biological medicine. The invention discloses a key action mechanism of circZFAND6 derived from TAMs exosome in the occurrence and development of the ovarian cancer. After the exosome circZFAND6 secreted by the TAMs is over-expressed and is taken by the ovarian cancer cells, the proliferation, migration and invasion capabilities of the cancer cells can be remarkably promoted; knock-down can effectively inhibit the malignant biological behaviors. According to the circZFAND6, the stability of c-Myc protein is maintained, glycolysis key enzyme expression regulated and controlled by c-Myc is up-regulated, the Warburg effect is enhanced, and the malignant progression of ovarian cancer is accelerated. The invention not only provides a solid theoretical basis and experimental evidence for the therapy strategy of the targeted circZFAND6 ovarian cancer, but also opens up a new direction for the intervention research of tumor metabolism reprogramming.
Owner:SHANDONG UNIV QILU HOSPITAL

Application of benzimidazolyl isoxazole compounds in the preparation of drugs related to multiple myeloma

The present invention relates to the application of a class of benzimidazolyl isoxazole compounds in the preparation of drugs related to multiple myeloma, belonging to the fields of medicinal chemistry and pharmacotherapy, and the compounds show good RPMI-8226 cell inhibitory activity. In addition, compound EP12 induces cell apoptosis and inhibits the expression of c-Myc mRNA and c-Myc protein, and circular dichroism spectroscopy experimental studies show that compound EP12 can stabilize c-Myc G4. The compound shown in formula I provided by the present invention, the isomer or a pharmaceutically acceptable salt thereof can be used in the preparation of drugs related to multiple myeloma.
Owner:XUZHOU MEDICAL UNIVERSITY

Phthalazinone GSPT1 protein degrading agent and use thereof

Disclosed is a compound as shown in general formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, and diastereomer thereof. The compound of the present invention significantly improves the degradation effect of GSPT1 protein and the anti-proliferative inhibition activity of AML and solid tumor cells. Therefore, the compound of the present invention can be used in the preparation of a medicament for treating or preventing diseases related to GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutation, expression imbalance, and allostery and functional abnormalities; in addition, said compound can be used to prepare a GSPT1 degrading agent.
Owner:CHINA PHARM UNIV +1

Application of MYC mRNA translation inhibitor in preparation of medicine for preventing and / or treating osteoarthritis

PendingCN121971624AEffectively regulate abnormal activation statusreduce degradationOrganic active ingredientsAntipyreticPharmaceutical drugMyc proteins
The invention belongs to the technical field of biological medicines, and particularly relates to application of an MYC mRNA translation inhibitor in preparation of a medicine for preventing and / or treating osteoarthritis. The MYC mRNA translation inhibitor is selected from biological materials capable of inhibiting or blocking the MYC mRNA translation process, reducing the MYC protein synthesis efficiency or interfering the MYC mRNA steady state level. The invention provides a novel molecular target capable of being used for treating osteoarthritis and a medicine application scheme of the molecular target.
Owner:NANCHANG UNIV

Application of MYC inhibitor in preparation of BET inhibitor sensitizing drug

The invention relates to the technical field of biological medicine, and discloses application of an MYC inhibitor in preparation of a BET inhibitor sensitizing drug. In order to screen a synergistic drug of a BET inhibitor, a core transcription factor for regulating a super enhancer (SE) is systematically screened, and it is found that MYC is a core main transcription factor of a tumor SE regulation network. Furthermore, experiments prove that the cancer inhibition effect of the BET inhibitor can be remarkably improved and the effective concentration of the BET inhibitor can be reduced by inducing and degrading endogenous MYC protein, inducing expression of negative dominant inhibition polypeptide Omomyc of MYC or treating with an MYC small-molecule inhibitor. Therefore, the MYC inhibitor can be used as a BET inhibitor sensitizing drug, and has a relatively good application prospect.
Owner:SHENZHEN UNIV

Pre-eclampsia diagnosis and treatment biological marker and application thereof

The invention discloses a preeclampsia (PE) diagnosis and treatment biological marker and an application of the preeclampsia PE diagnosis and treatment biological marker. The mechanism that overexpressed FBP2 causes PE generation by inhibiting trophoblast invasiveness is deeply demonstrated from clinical samples, cells and in-vivo levels, it is verified that NOTCH3 downstream classical gene HEY1 can be combined with an FBP2 promoter region and transcriptionally inhibits expression of the FBP2, the FBP2 is combined with c-MYC protein and inhibits c-MYC transcriptional activity, TFAM transcriptional expression is down-regulated, and the expression of the FBP2 is inhibited. The mechanism which causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts and participates in PE generation is a new mechanism clue obtained according to a pre-experiment result and informatics analysis and is a new target for deeply exploring PE clinical diagnosis and treatment, and research results can provide a theoretical basis for guiding PE early prediction and intervention in the future.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL

Degradation agent targeting c-Myc protein, and preparation method and application of polypeptide drug coupled with nano-selenium

The invention provides a c-Myc protein targeting degradation agent and a preparation method and application of a nano-selenium coupled polypeptide drug, and belongs to the technical field of biological medicines. The amino acid sequence of the degradation agent is shown as SEQ ID NO: 1, the binding constant of the degradation agent and c-Myc protein is 40.18 nM, and it is indicated that the degradation agent has high binding capacity with the c-Myc protein. The degradation agent or the polypeptide drug coupled with the nano-selenium is delivered into tumor cells, c-Myc protein can be effectively degraded, and the capability of remarkably inhibiting tumor growth and inducing tumor cell apoptosis is shown. Therefore, the preparation method of the degradation agent or the polypeptide drug coupled with nano-selenium can be applied to preparation of drugs for preventing and / or treating c-Myc protein disorder related diseases such as tumors or preparation of reagents for degrading c-Myc protein, and has very wide application value and patent medicine prospect.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV

A biological marker for diagnosis and treatment of preeclampsia and application thereof

The application discloses a kind of preeclampsia (Preeclampsia, PE) diagnosis and treatment biology marker and its application;The application is from clinical sample, cell and in-depth demonstration of overexpressed FBP2 at the level of body, which causes the mechanism of PE occurrence by inhibiting the invasion of trophoblasts, and the application verifies that the classic gene HEY1 downstream of NOTCH3 can be combined with the promoter region of FBP2 and transcribe to inhibit the expression of FBP2, FBP2 is combined with c-MYC protein and inhibits the transcriptional activity of c-MYC, down-regulates the transcriptional expression of TFAM, causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts, participates in the mechanism of PE occurrence, is a new mechanism clue obtained according to the results of pre-experiment and information analysis, is a new target for in-depth exploration of PE clinical diagnosis and treatment, and the research results can provide theoretical basis for guiding early prediction and intervention of PE in the future.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL

Nucleic acid aptamer combined with WDR5 protein and application thereof

The invention provides a nucleic acid aptamer combined with WDR5 protein and application of the nucleic acid aptamer, and relates to the technical field of biology, the nucleic acid aptamer which is small in molecular weight, stable in chemical property, easy to store and mark and capable of being combined with the WDR5 protein with high affinity and high specificity is obtained by conducting chemical modification and screening on the nucleic acid aptamer. The specific site WBM of the nucleic acid aptamer, which is combined with the WDR5 protein, is defined; the combination of WDR5 and MYC protein can be blocked, so that the aggregation of MYC to chromatin can be prevented; the structure is relatively stable and simple, modification is easy, artificial synthesis can be carried out in a short time, chemical properties are stable, and storage and marking are easy; the method can be used for detection, diagnosis, imaging, treatment and the like, and has wide application prospects.
Owner:ZHEJIANG UNIV OF TECH +1

Application of YW2301 in preparation of medicine for resisting Burkitt lymphoma

The invention discloses an application of YW2301 in preparation of a medicine for resisting Burkitt lymphoma. CCK8 cell viability experiments are utilized to detect that the YW2301 has inhibition capability on Raji and CA46 cell proliferation; a Raji cell line is used for constructing a NON / SCID subcutaneous transplantation tumor model, the therapeutic significance of the YW2301 on Burkitt lymphoma is evaluated, and the YW2301 can effectively inhibit the tumorigenicity of Burkitt lymphoma cells and the growth speed of transplantation tumors; according to the present invention, the ALDH18A1 and c-Myc protein expression in the Burkitt lymphoma transplantation tumor tissue section is detected by using immunohistochemical staining, and the YW2301 can effectively down-regulate the ALDH18A1 and c-Myc protein expression in the Burkitt lymphoma tissue so as to further prove that the YW2301 can be used as the candidate small molecule for the Burkitt lymphoma targeted therapy;
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

Nanoparticle formulations

This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
Owner:HTYR ACQUISITION LLC

Inhibitors of MYC and their use

A substituted heterocyclic compound and a proteolysis-targeting chimera molecule (PROTAC) are disclosed. The substituted heterocycles disclosed herein are shown to be useful for inhibiting c-MYC. The disclosed PROTACs have been shown to induce the degradation of c-MYC protein. The substituted heterocyclic compounds and proteolysis-targeting chimera molecules (PROTACs) disclosed herein can be utilized as therapeutic agents for treating cancer and cell proliferative disorders.
Owner:NORTHWESTERN UNIV

Phthalazinone GSPT1 protein degrading agent and use thereof

PendingAU2024371961B2DiseaseMedicine
Disclosed is a compound as shown in general formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, and diastereomer thereof. The compound of the present invention significantly improves the degradation effect of GSPT1 protein and the anti-proliferative inhibition activity of AML and solid tumor cells. Therefore, the compound of the present invention can be used in the preparation of a medicament for treating or preventing diseases related to GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutation, expression imbalance, and allostery and functional abnormalities; in addition, said compound can be used to prepare a GSPT1 degrading agent.
Owner:CHINA PHARM UNIV +1

Protein degradation agent

PCT designated stage expiredWO2024027694A9Organic active ingredientsOrganic chemistryDiseaseMyc proteins
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention and treatment of diseases related to disorders of various proteins including c-Myc protein, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection-related diseases.
Owner:SUZHOU KINTOR PHARMA

Construction method of gastric adenocarcinoma transgenic mouse model and application thereof

ActiveCN119174414BCompound screeningApoptosis detectionStainingActivating mutation
The application discloses a kind of gastric adenocarcinoma transgenic mouse model construction method and its application, the construction method includes the following steps: using transgenic and hybridization technology, MYC gene expression quantity or MYC protein activity in mouse gastric mucosa layer epithelial cell is overexpressed or increased, KRAS gene mutant type in gastric mucosa layer epithelial cell is activated simultaneously, make Kras protein function abnormal, continuously in activated state, finally obtained mouse is gastric adenocarcinoma transgenic mouse model.The application constructs Myc gene overexpression and KRAS activation mutation double gene mutation mouse spontaneous gastric cancer animal model, method is simpler.This mouse model of gastric cancer tumorigenesis time is shortened, tumorigenic rate is as high as 100%, and tumorigenic effect is stable.And after induction, only in stomach tumorigenesis, tumorigenesis has high specificity.Pathological section and immunohistochemical staining determine that this animal model is adenocarcinoma in gastric cancer, has good clinical representativeness, can be applied to the application in later development or screening gastric cancer drug.
Owner:SHANDONG UNIV

Application of compound Y500-3645 as c-Myc protein degradation agent in preparation of drugs for resisting multiple myeloma

The invention relates to application of a compound Y500-3645 as a c-Myc protein degradation agent in preparation of a drug for resisting multiple myeloma, and belongs to the technical field of multiple myeloma. The pharmaceutical composition for treating multiple myeloma provided by the invention takes a compound shown as a formula Y500-3645 or pharmaceutically acceptable salt thereof as an active ingredient or a main active ingredient, and is supplemented with a pharmaceutically acceptable carrier. In multiple myeloma, the compound Y500-3645 inhibits the expression of c-Myc by promoting the degradation of c-Myc protein, regulates the expression levels of mRNA and protein of related genes, and promotes the death of myeloma cells. As a drug for resisting multiple myeloma, a new thought is provided for research and development of the drug for resisting multiple myeloma. # imgabs0 #
Owner:ANHUI UNIV OF SCI & TECH

A small molecule degrader of arylformamidines and uses thereof

The application discloses a small molecule degrading agent of aryl formamides and application thereof, and has a structure shown in general formula I or a pharmaceutically acceptable salt, an isotopically labeled compound thereof. The compound of the application has a targeted degradation activity on MYC protein, and has a significant proliferation inhibiting activity on various solid tumor cells such as neuroblastoma and rhabdomyosarcoma. The compound of the application can be used for preparing a degrading agent targeting MYC protein, and can also be used for preparing a drug for treating diseases related to MYC gene amplification, fusion, mutation, expression imbalance, conformational change and function abnormality.
Owner:ZHEJIANG UNIV

Syringin targeted inhibition DLAT protein and application of syringin targeted inhibition DLAT protein in inhibition of mycobacterium tuberculosis

The invention belongs to the technical field of medicines, and particularly relates to syringin targeted inhibition DLAT protein and application of syringin targeted inhibition DLAT protein in inhibition of mycobacterium tuberculosis. Research finds that natural micromolecule syringin can inhibit DLAT protein activity in a targeted manner, reduce acetylation of MYC protein and promote ubiquitination and degradation of MYC protein, so that the MYC protein level is reduced, M2 type polarization of macrophages is inhibited, the polarization state of the macrophages is adjusted, growth of mycobacterium tuberculosis in the macrophages is inhibited, and the MYC-MYC-MYC-MYC-MYC-MYC-MYC-MYC-MYC-MYC is inhibited. The anti-tuberculosis effect is effectively achieved. Compared with an existing anti-tuberculosis technology, the anti-tuberculosis scheme is clear in action mechanism and accurate in targeting effect, and blindness of a traditional therapy is avoided. According to the present invention, the tuberculosis condition can be effectively controlled, the treatment period is expected to be shortened, the physical, mental and economic burden of the patient is reduced, the untoward effect risk is substantially reduced due to the high biological safety of the natural small molecules, and the new reliable path is provided for the clinical anti-tuberculosis treatment.
Owner:GUANGZHOU UNIVERSITY

An isolated polypeptide and uses thereof

The application provides an isolated polypeptide and application thereof, and the polypeptide comprises an amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with the amino acid sequence shown in SEQ ID NO: 2. The isolated polypeptide can specifically bind to a c-Myc protein, destroy the stabilizing effect of RALY on the c-Myc protein, promote the degradation of the c-Myc protein through a ubiquitin-proteasome pathway, inhibit the proliferation of cancer cells, reduce the survival ability of the cancer cells, and can effectively prevent and / or treat tumors.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT +1

Nanoparticle formulations

This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
Owner:HTYR ACQUISITION LLC